Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study

The response to icotinib in advanced non‐small cell lung cancers (NSCLC) with EGFR uncommon mutation (EGFRum) is unclear. Here we reported the efficacy and potential resistance mechanism of icotinib in Chinese EGFRum NSCLC patients. Between July 2013 and November 2016, 3117 NSCLC patients were scree...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Lei, Wang, Wen‐xian, Zhu, You‐cai, Li, Jin‐luan, Fang, Yong, Wang, Hong, Zhuang, Wu, Zhang, Yin‐bin, Wang, Li‐ping, Fang, Mei‐yu, Xu, Chun‐wei, Wang, Xiao‐jia, Lv, Tang‐feng, Song, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943154/
https://www.ncbi.nlm.nih.gov/pubmed/31692291
http://dx.doi.org/10.1002/cam4.2652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943154/
https://www.ncbi.nlm.nih.gov/pubmed/31692291
http://dx.doi.org/10.1002/cam4.2652

Ejemplares similares